Neurotoxic properties of new antitumor agent anthrafuran
https://doi.org/10.17650/1726-9784-2019-18-1-75-79
Abstract
Introduction . Currently, the study of the neurotoxic properties of new drugs is an indispensable step towards the promotion of the medicine to clinical practice. The original antitumor drug anthrafuran (LCTA-2034), obtained in Gause Institute of New Antibiotics, has demonstrated high activity against transplantable mice tumors. Previous studies have shown that the drug in high doses causes brain tissues damage.
Objective: a pilot investigation of anthrafuran neurotoxicity.
Materials and methods . The study was carried out on 52 female outbred rats. The suspension of drug in water for injection was administrated per os at a single maximum tolerated dose of 170 mg/kg. The testing was performed on “open field” setting 1, 4 and 8 h and repeated on day 1 and 30 post treatment.
Results . It was found that the administration of the drug reduced both motor (covered distance, average speed) and research (the number of rearings, contacts with the “burrow”) activity as compared to control. These effects were manifested to the greatest extent 4 h post treatment. A day later, when rats re-visit “open field”, the parameters under study increased in this group, while in the control group these indicators decreased.
Conclusion . Anthrafuran exhibits a reversible inhibitory effect on the motor and research activity of rats.
About the Authors
V. A. Golibrodo
Gause Institute of New Antibiotics
Russian Federation
Build. 1, 11 Bol’shaya Pirogovskaya St., Moscow 119021
Russian Federation
Build. 1, 11 Bol’shaya Pirogovskaya St., Moscow 119021
I. D. Treshchalin
Gause Institute of New Antibiotics
Russian Federation
Build. 1, 11 Bol’shaya Pirogovskaya St., Moscow 119021
Russian Federation
Build. 1, 11 Bol’shaya Pirogovskaya St., Moscow 119021
A. E. Shchekotikhin
Gause Institute of New Antibiotics
Russian Federation
Build. 1, 11 Bol’shaya Pirogovskaya St., Moscow 119021
Russian Federation
Build. 1, 11 Bol’shaya Pirogovskaya St., Moscow 119021
E. R. Pereverzeva
Gause Institute of New Antibiotics
Russian Federation
Build. 1, 11 Bol’shaya Pirogovskaya St., Moscow 119021
Russian Federation
Build. 1, 11 Bol’shaya Pirogovskaya St., Moscow 119021
References
1. Корман Д.Б. Основы противоопухолевой химиотерапии. М.: Практическая медицина, 2006. 512 с. [Korman D.B. Basics of anticancer chemotherapy. Мoscow: Practical medicine, 2006. 512 р. (In Russ.)].
2. Семенова А.И. Кардиои нейротоксичность противоопухолевых препаратов (патогенез, клиника, профилактика, лечение). Практическая онкология 2009;10(3):168–76. [Semenova A.I. Cardioand neurotoxicity of antitumor drugs (pathogenesis, clinic, prophylaxis, treatment). Prakticheskaya onkologiya = Practical Oncology 2009;10(3):168–76. (In Russ.)].
3. Amptoulach S., Tsavaris N. Neurotoxicity caused by the treatment with platinum analogues. Chemother Res Pract 2011;2011:843019. DOI: 10.1155/2011/843019. PMID: 22312559.
4. Baudino B., D’agata F., Caroppo P. et al. The chemotherapy long-term effect on cognitive functions and brain metabolism in lymphoma patients. Q J Nucl Med Mol Imaging 2012;56(6):559–68. PMID: 23172518.
5. Vichaya E.G., Chiu G.S., Krukowski K. et al. Mechanisms of chemotherapyinduced behavioral toxicities. Front Neurosci 2015;9:131. DOI: 10.3389/fnins.2015.00131. PMID: 25954147.
6. Yang M., Moon C. Neurotoxicity of cancer chemotherapy. Neural Regen Res 2013;8(17):1606–14. DOI: 10.3969/j.issn.1673-5374. 2013.17.009. PMID: 25206457.
7. Boehmerle W., Huehnchen P., Peruzzaro S. et al. Electrophysiological, behavioral and histological characterization of paclitaxel, cisplatin, vincristine and bortezomib-induced neuropathy in C57Bl/6 mice. Sci Rep 2014;4:6370. DOI: 10.1038/srep06370. PMID: 25231679.
8. Höke A., Ray M. Rodent models of chemotherapy-induced peripheral neuropathy. ILAR J 2014;54(3):273–81. DOI: 10.1093/ilar/ilt053. PMID: 24615440.
9. Moser V.C. Functional Assays for Neurotoxicity Testing. Toxicol Pathol 2011;39(1):36–45. DOI: 10.1177/0192623310385255. PMID: 21075917.
10. Абрашова Т.В., Гущин Я.А., Ковалева М.А. и др. Физиологические, биохимические и биометрические показатели нормы экспериментальных животных. Справочник. СПб.: ЛЕМА, 2013. 116 c. [Abrashova T.V., Gushchin Ya.A., Kovaleva M.A. et al. Physiological, biochemical and biometric indicators of experimental animals. Handbook. St. Petersburg: LEMA, 2013. 116 p. (In Russ.)].
11. Буреш Я., Бурешова О., Хьюстон Д.П. Методики и основные эксперименты по изучению мозга и поведения. М.: Высшая школа, 1991. 399 c. [Buresh Ya., Bureshova O., Houston D.P. Techniques and basic experiments in studying of brain and behavior. Moscow: Higher School, 1991. 399 p. (In Russ.)].
12. Tikhomirov A.S., Shtil A.A., Shchekotikhin A.E. Advances in the discovery of anthraquinone-based anticancer agents. Recent Pat Anticancer Drug Discov 2018;13(2):159–83. DOI: 10.2174/157489281366617120612 3114. PMID: 29210664.
13. Treshalina H.M., Romanenko V.I., Kaluzhny D.N. et al. Development and pharmaceutical evaluation of the anticancer Anthrafuran/Cavitron complex, a prototypic parenteral drug formulation. Eur J Pharm Sci 2017;109:631–7. DOI: 10.1016/j.ejps.2017.09.025. PMID: 28927751.
14. Shchekotikhin A.E., Dezhenkova L.G., Tsvetkov V.B. et al. Discovery of antitumor anthra[2,3-b]furan-3-carboxamides: optimization of synthesis and evaluation of antitumor properties. Eur J Med Chem 2016;112:114–29. DOI: 10.1016/j.ejmech.2016.01.050. PMID: 26890118.
15. Трещалин М.И., Трещалин И.Д., Голибродо В.А. и др. Экспериментальная оценка токсических свойств ЛХТА-2034 при пероральном применении. Российский биотерапевтический журнал 2018;17(3):81–8. [Treschalin M.I., Treschalin I.D., Golibrodo V.A. et al. Experimental evaluation of toxic properties of LCTA-2034 by the oral route of administration. Rossiysky bioterapevtichesky zhurnal = Russian Journal of Biotherapy 2018;17(3):81–8. (In Russ.)]. DOI: 10.17650/1726-9784-2018-17-3-81-88.
16. Руководство по проведению доклинических исследований лекарственных средств. Под ред. А.Н. Миронова. Часть 1. М.: Гриф и Ко, 2012. C. 13–24. [Guideline for preclinical studies of drugs. Ed. A.N. Mironov. Part I. Moscow: Grif & K, 2012. Pp. 13–24. (In Russ.)].
17. Правила надлежащей лабораторной практики. Приказ Министерства здравоохранения РФ от 1 апреля 2016 г. No 199н. [The rules of good laboratory practice. Order of the Ministry of Health of the Russian Federation, April 1, 2016, No. 199n. (In Russ.)].
18. Council of Europe. European Convention for the protection of vertebrate animals used for experimental and other scientific purposes. ETS 1986:123.
19. Щекотихин А.Е., Трещалина Е.М., Трещалин И.Д. Пероральные противоопухолевые средства и способ лечения онкологических заболеваний. Патент РФ No 2639479 от 21.12.2017. [Shchekotikhin A.E., Treshchalina E.M., Treshchalin I.D. Oral antitumour drugs and method for oncological diseases treatment. Patent RF No. 2639479, 21.12.2017. (In Russ.)].
20. Alimoradi H., Pourmohammadi N., Mehr S.E. et al. Effects of lithium on peripheral neuropathy induced by vincristine in rats. Acta Med Iran 2012;50(6):373–9. PMID: 22837115.
21. Barzegar-Fallah A., Alimoradi H., Mehrzadi S. et al. The neuroprotective effect of tropisetron on vincristineinduced neurotoxicity. Neurotoxicology 2014;41:1–8. DOI: 10.1016/j.neuro.2013.12.002. PMID: 24374478.
22. Pourmohammadi N., Alimoradi H., Mehr S.E. et al. Lithium attenuates peripheral neuropathy induced by paclitaxel in rats. Basic Clin Pharmacol Toxicol 2012;110(3):231–7. DOI: 10.1111/j.1742-7843.2011.00795.x. PMID: 21917116.
23. Liedke P.E., Reolon G.K., Kilpp B. et al. Systemic administration of doxorubicin impairs aversively motivated memory in rats. Pharmacol Biochem Behav 2009;94(2):239–43. DOI: 10.1016/j.pbb.2009.09.001. PMID: 19747935.
24. Jangra A., Kwatra M., Singh T. et al. Edaravone alleviates cisplatin-induced neurobehavioral deficits via modulation of oxidative stress and inflammatory mediators in the rat hippocampus. Eur J Pharmacol 2016;791:51–61. DOI: 10.1016/j.ejphar.2016.08.003. PMID: 27492363.
Review
For citations:
Golibrodo V.A., Treshchalin I.D., Shchekotikhin A.E., Pereverzeva E.R. Neurotoxic properties of new antitumor agent anthrafuran. Russian Journal of Biotherapy. 2019;18(1):75-79. (In Russ.) https://doi.org/10.17650/1726-9784-2019-18-1-75-79
Views:
507
Email this article 
